The Chile Biliary Longitudinal Study: A Gallstone Cohort.


Journal

American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653

Informations de publication

Date de publication:
01 02 2021
Historique:
received: 13 04 2020
revised: 09 09 2020
accepted: 10 09 2020
entrez: 1 2 2021
pubmed: 2 2 2021
medline: 25 2 2021
Statut: ppublish

Résumé

Gallbladder cancer (GBC) is a highly fatal cancer that can be cured through cholecystectomy if identified early. The presence of gallstones is the primary risk factor for GBC, but few people with gallstones develop GBC. A key question is what drives the development of GBC among persons with gallstones. We initiated the Chile Biliary Longitudinal Study (Chile BiLS) to address this question. From 2016 to 2019, Chile BiLS enrolled 4,726 women aged 50-74 years with ultrasound-detected gallstones from southern-central Chile, accounting for an estimated 36% of eligible women with gallstones in the study area. The median age was 59 years; 25% of the women were Amerindian (Mapuche), 60% were obese, 25% had diabetes, and 6% had cardiovascular disease. Participants will be followed for gallbladder dysplasia or cancer for 6 years. As of April 30, 2020, over 91% of those eligible completed the year 2 follow-up visit. Data being collected include epidemiologic and sociodemographic information, anthropometric measurements, blood pressure, and tooth counts. Biosamples being taken include baseline plasma, buffy coat, red blood cells, serum, blood clot from serum, and PAXgene whole blood (PreAnalytiX GmbH, Hombrechtikon, Switzerland). Complete gallbladder sampling is conducted for most participants undergoing cholecystectomy. The Chile BiLS cohort study will increase our understanding of GBC etiology and could identify potential risk stratification and early detection strategies in high-risk areas.

Identifiants

pubmed: 33524121
pii: 5905931
doi: 10.1093/aje/kwaa199
pmc: PMC7850058
doi:

Substances chimiques

Inflammation Mediators 0

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

196-206

Informations de copyright

Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Références

Indian J Surg. 2012 Feb;74(1):4-12
pubmed: 23372301
Ann Oncol. 2009 Jan;20(1):146-59
pubmed: 18667395
Int J Cancer. 2010 Nov 15;127(10):2446-54
pubmed: 20473911
Hepatology. 2020 Mar;71(3):917-928
pubmed: 31318976
Rev Med Chil. 1995 May;122(5):531-6
pubmed: 7724893
Surgeon. 2008 Apr;6(2):101-10
pubmed: 18488776
BMC Public Health. 2016 Feb 04;16:122
pubmed: 26847446
J Surg Oncol. 2006 Jun 15;93(8):615-23
pubmed: 16724345
Cancer. 2019 May 1;125(9):1489-1498
pubmed: 30645774
Sci Rep. 2018 Apr 4;8(1):5671
pubmed: 29618736
Rev Med Chil. 2002 Jul;130(7):723-30
pubmed: 12235895
Cancer Epidemiol. 2016 Sep;44 Suppl 1:S82-S89
pubmed: 27678326
Cancer Causes Control. 2008 Feb;19(1):33-41
pubmed: 17906958
N Engl J Med. 1982 Sep 23;307(13):798-800
pubmed: 7110244
Gastroenterology. 1966 Mar;50(3):376-81
pubmed: 5905358
CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64
pubmed: 11760569
Cancer Epidemiol. 2018 Jun;54:25-30
pubmed: 29554539
Nat Rev Cancer. 2004 Sep;4(9):695-706
pubmed: 15343276
Int J Cancer. 2006 Apr 1;118(7):1591-602
pubmed: 16397865
Int J Epidemiol. 2020 Jun 1;49(3):760-761i
pubmed: 32176288
Hum Pathol. 2018 Dec;82:87-94
pubmed: 30036595
JAMA Oncol. 2019 Oct 17;:
pubmed: 31621809
Curr Gastroenterol Rep. 2005 May;7(2):132-40
pubmed: 15802102
Int J Cancer. 2020 Aug 15;147(4):978-989
pubmed: 31922259
J Gastroenterol Hepatol. 2010 Apr;25(4):719-24
pubmed: 20492328
Cytokine. 2016 Jul;83:217-225
pubmed: 27173614
Gastroenterology. 2017 Aug;153(2):488-494.e1
pubmed: 28428144
Ann Intern Med. 1987 Jul;107(1):30-5
pubmed: 3592446
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):597-606
pubmed: 28314823
JAMA. 2015 May 26;313(20):2075-7
pubmed: 26010638
Biochim Biophys Acta. 2016 Apr;1865(2):245-54
pubmed: 26980625
Lancet. 2019 Jun 8;393(10188):2322-2330
pubmed: 31036336
Am J Epidemiol. 2014 Mar 15;179(6):731-9
pubmed: 24470530
J Hepatol. 2020 Oct;73(4):863-872
pubmed: 32437829
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Cancer Med. 2016 Nov;5(11):3310-3235
pubmed: 27726295
Cancer Res. 2019 Aug 1;79(15):3973-3982
pubmed: 31113819

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH